In a significant legislative development, the House Appropriations Committee has approved a funding bill that includes a provision explicitly designed to block the federal rescheduling of marijuana. This move creates a direct conflict with the current trajectory of the executive branch, as the Trump administration recently announced its intention to proceed with the formal rescheduling process. The legislative rider seeks to strip the Department of Justice and other federal agencies of the authority to finalize or implement any rule-making that would move cannabis from Schedule I to a lower classification under the Controlled Substances Act.
For industry stakeholders, this creates a state of significant regulatory instability. While the executive branch is actively signaling a path toward reform—which could drastically alter tax implications under Section 280E and facilitate easier banking access—the legislative branch is exercising its power of the purse to halt those efforts. If this provision remains in the final passed budget, it effectively renders the administration’s rescheduling efforts moot, as the agencies involved would lack the funding necessary to carry out the policy change.
This stalemate suggests a prolonged period of federal legal uncertainty. Industry observers are now tracking the bill’s progress through the remainder of the congressional cycle to see if the rider survives final negotiations or if the executive branch will push back against this attempt to undermine its regulatory agenda. Businesses operating within the cannabis space should prepare for a continued reliance on current state-legal frameworks, as federal reform remains caught in a high-stakes power struggle between the White House and Capitol Hill.
The potential for a sudden shift in the federal landscape remains, but investors and operators should temper expectations regarding immediate improvements to the federal tax and banking environment until a resolution is reached.